1. Shareholders approved 5 directors for Willow Biosciences Inc. 2. KPMG LLP appointed as auditor for the upcoming year. 3. Shareholders approved selling shares of Epimeron USA, Inc. 4. Name change proposal for the company received significant support. 5. Meeting saw representation of about 40.88% of shares.
The approval of directors signifies shareholder confidence. Historical patterns show positive price reactions post-shareholder meetings with strategic decisions.
The outcomes from the meeting underline corporate governance and strategic direction, essential for investor sentiment.
Immediate shareholder decisions can enhance market perception, influencing quick trading activity. Past similar announcements have shown short-term gains in related stocks.
("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the "Meeting"). A total of 59,214,893 common shares, representing approximately 40.88% of the Company's issued and outstanding shares were represented at the meeting.
The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
| Director | Votes For | Votes Withheld |
|---|---|---|
| Dr. Chris Savile | 46,902,346 (88.3 %) | 6,234,676 (11.7 %) |
| Dr. Jim Lalonde | 46,965,380 (88.4 %) | 6,171,642 (11.6 %) |
| Donald Archibald | 44,900,287 (84.5 %) | 8,236,735 (15.5 %) |
| Raffi Asadorian | 46,963,057 (88.4 %) | 6,173,965 (11.6 %) |
| Al Foreman | 46,900,723 (88.3 %) | 6,236,299 (11.7 %) |
In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company's management information circular dated March 26, 2025 (the "Information Circular").
| Matter | Votes For |
|---|---|
| Appointment of KPMG LLP as the Company's auditor for the ensuring year | 51,882,364 (87.6 %) |
| The proposed sale of the shares of Epimeron USA, Inc., the Corporation's wholly-owned subsidiary, as more particularly described in the Information Circular | 46,996,397 (88.4 %) |
| To authorize the Corporation's board of directors, at its sole discretion, to amend the Articles of the Corporation to change its name from "Willow Biosciences Inc." to "2482118 Alberta Ltd.", or such other name as may be approved by the Board, as more particularly described in the Information Circular. | 48,853,362 (82.5 %) |
For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated April 25, 2025, available on SEDAR+ at www.sedarplus.ca.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage, and personal care markets. Willow's FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
For more information, visit www.willowbio.com or contact:
Travis Doupe
Chief Financial Officer
E: [email protected]
SOURCE Willow Biosciences Inc.